| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
St. Vincents Institute of Medical Research and The University of Melbourne, Department of Medicine, St. Vincents Hospital, Fitzroy, Victoria 3065, Australia
Address all correspondence and requests for reprints to: Matthew T. Gillespie, St. Vincents Institute of Medical Research, The University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia. E-mail: m.gillespie{at}medicine.unimelb.edu.au
The osteoclastogenic factor of osteoblastic origin has recently been elucidated as a novel Tumor Necrosis Factor (TNF)-ligand family member, termed osteoclast differentiation factor (ODF). Using a semiquantitative RT-PCR approach, we sought to determine the mRNA expression of ODF and its decoy receptor, osteoprotegerin (OPG), in a selection of osteoblastic cell lines and in response to three factors representative of different signal transduction pathways, vitamin D receptor, protein kinase A or gp130. Each osteotropic agent, either 1,25-(OH)2D3, PTH or IL-11, promoted an increase in the ratio of ODF:OPG, with maximal stimulation occurring at 24h, 4h, and 8h, respectively, and furthermore each was shown to act in a dose-dependent manner. This report establishes that osteoblastic cell lines incapable of supporting osteoclast formation have markedly reduced ODF expression and also illustrates the importance of the relative abundance of ODF compared with the levels of OPG for the induction of osteoclastogenesis.
This article has been cited by other articles:
![]() |
R. E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, and W. C. Dougall RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis Mol. Cancer Ther., July 1, 2008; 7(7): 2160 - 2169. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-K. Jun, Y.-M. Kang, H.-R. Lee, S.-H. Lee, and B.-K. Choi Highly Conserved Surface Proteins of Oral Spirochetes as Adhesins and Potent Inducers of Proinflammatory and Osteoclastogenic Factors Infect. Immun., June 1, 2008; 76(6): 2428 - 2438. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. M. Sutton, X. Zhang, D. R. Dowd, Y. P. Kharode, B. S. Komm, and P. N. MacDonald Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3-Induced Gene in Osteoblasts that Promotes Osteoclastogenesis and Induces Osteopenia in Mice Mol. Endocrinol., June 1, 2008; 22(6): 1370 - 1381. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Kingsley, P. G.J. Fournier, J. M. Chirgwin, and T. A. Guise Molecular Biology of Bone Metastasis Mol. Cancer Ther., October 1, 2007; 6(10): 2609 - 2617. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Pickard, A. B. Hodsman, L. J. Fraher, and P. H. Watson Type 1 Parathyroid Hormone Receptor (PTH1R) Nuclear Trafficking: Association of PTH1R with Importin {alpha}1 and {beta} Endocrinology, July 1, 2006; 147(7): 3326 - 3332. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lee, J. S. Finkelstein, M. Miller, S. J. Comeaux, R. I. Cohen, and B. Z. Leder Effects of Selective Testosterone and Estradiol Withdrawal on Skeletal Sensitivity to Parathyroid Hormone in Men J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1069 - 1075. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Young, N. Mikhalkevich, Y. Yan, D. Chen, and W.-p. Zheng Differential Regulation of Osteoblast Activity by Th Cell Subsets Mediated by Parathyroid Hormone and IFN-{gamma} J. Immunol., December 15, 2005; 175(12): 8287 - 8295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lossdorfer, W. Gotz, and A. Jager PTH(1-34) Affects Osteoprotegerin Production in Human PDL Cells in vitro J. Dent. Res., July 1, 2005; 84(7): 634 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Normanno, A De Luca, D Aldinucci, M R Maiello, M Mancino, A D'Antonio, R De Filippi, and A Pinto Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis Endocr. Relat. Cancer, June 1, 2005; 12(2): 471 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nataf, A. Anginot, C. Vuaillat, L. Malaval, N. Fodil, E. Chereul, J.-B. Langlois, C. Dumontel, G. Cavillon, C. Confavreux, et al. Brain and Bone Damage in KARAP/DAP12 Loss-of-Function Mice Correlate with Alterations in Microglia and Osteoclast Lineages Am. J. Pathol., January 1, 2005; 166(1): 275 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Buxton, W. Yao, and N. E. Lane Changes in Serum Receptor Activator of Nuclear Factor-{kappa}B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1-34) J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3332 - 3336. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Onyia, R. J. S. Galvin, Y. L. Ma, D. L. Halladay, R. R. Miles, X. Yang, T. Fuson, R. L. Cain, Q. Q. Zeng, S. Chandrasekhar, et al. Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 369 - 379. [Abstract] [Full Text] |
||||
![]() |
U. H. Lerner NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION Crit. Rev. Oral. Biol. Med., March 1, 2004; 15(2): 64 - 81. [Abstract] [Full Text] |
||||
![]() |
A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, and N. Horiuchi Leptin Corrects Increased Gene Expression of Renal 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase and -24-Hydroxylase in Leptin-Deficient, ob/ob Mice Endocrinology, March 1, 2004; 145(3): 1367 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Suda, N. Udagawa, N. Sato, M. Takami, K. Itoh, J.-T. Woo, N. Takahashi, and K. Nagai Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation J. Immunol., February 15, 2004; 172(4): 2504 - 2510. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Fan, E. Roy, L. Zhu, T. C. Murphy, C. Ackert-Bicknell, C. M. Hart, C. Rosen, M. S. Nanes, and J. Rubin Nitric Oxide Regulates Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin Expression in Bone Marrow Stromal Cells Endocrinology, February 1, 2004; 145(2): 751 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Bergh, Y. Xu, and M. C. Farach-Carson Osteoprotegerin Expression and Secretion Are Regulated by Calcium Influx through the L-Type Voltage-Sensitive Calcium Channel Endocrinology, January 1, 2004; 145(1): 426 - 436. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chiusaroli, A. Maier, M. C. Knight, M. Byrne, L. M. Calvi, R. Baron, S. M. Krane, and E. Schipani Collagenase Cleavage of Type I Collagen Is Essential for Both Basal and Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor-Induced Osteoclast Activation and Has Differential Effects on Discrete Bone Compartments Endocrinology, September 1, 2003; 144(9): 4106 - 4116. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zou, A. Amcheslavsky, and Z. Bar-Shavit CpG Oligodeoxynucleotides Modulate the Osteoclastogenic Activity of Osteoblasts via Toll-like Receptor 9 J. Biol. Chem., May 2, 2003; 278(19): 16732 - 16740. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-K. Choi, H. J. Lee, J. H. Kang, G. J. Jeong, C. K. Min, and Y.-J. Yoo Induction of Osteoclastogenesis and Matrix Metalloproteinase Expression by the Lipooligosaccharide of Treponema denticola Infect. Immun., January 1, 2003; 71(1): 226 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gurlek, M. R. Pittelkow, and R. Kumar Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1{alpha},25-Dihydroxyvitamin D3: Implications in Cell Growth and Differentiation Endocr. Rev., December 1, 2002; 23(6): 763 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamashita, S. Okada, K. Higashio, Y.-i. Nabeshima, and M. Noda Double Mutations in Klotho and Osteoprotegerin Gene Loci Rescued Osteopetrotic Phenotype Endocrinology, December 1, 2002; 143(12): 4711 - 4717. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-{kappa}B Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvariae J. Immunol., September 15, 2002; 169(6): 3353 - 3362. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Geoffroy, M. Kneissel, B. Fournier, A. Boyde, and P. Matthias High Bone Resorption in Adult Aging Transgenic Mice Overexpressing Cbfa1/Runx2 in Cells of the Osteoblastic Lineage Mol. Cell. Biol., September 1, 2002; 22(17): 6222 - 6233. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Peleg, M. Uskokovic, A. Ahene, B. Vickery, and Z. Avnur Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats Endocrinology, May 1, 2002; 143(5): 1625 - 1636. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers TNF{alpha} Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL Endocrinology, March 1, 2002; 143(3): 1108 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Coen, P. Ballanti, A. Balducci, S. Calabria, M. S. Fischer, L. Jankovic, M. Manni, M. Morosetti, E. Moscaritolo, D. Sardella, et al. Serum osteoprotegerin and renal osteodystrophy Nephrol. Dial. Transplant., February 1, 2002; 17(2): 233 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Pettit, H. Ji, D. von Stechow, R. Muller, S. R. Goldring, Y. Choi, C. Benoist, and E. M. Gravallese TRANCE/RANKL Knockout Mice Are Protected from Bone Erosion in a Serum Transfer Model of Arthritis Am. J. Pathol., November 1, 2001; 159(5): 1689 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
U Feige Osteoprotegerin Ann Rheum Dis, November 1, 2001; 60(90003): iii81 - 84. [Full Text] [PDF] |
||||
![]() |
P. J. Kostenuik, C. Capparelli, S. Morony, S. Adamu, G. Shimamoto, V. Shen, D. L. Lacey, and C. R. Dunstan OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats Endocrinology, October 1, 2001; 142(10): 4295 - 4304. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Watkins, Y. Li, and M. F. Seifert Nutraceutical Fatty Acids as Biochemical and Molecular Modulators of Skeletal Biology J. Am. Coll. Nutr., October 1, 2001; 20(90005): 410S - 416. [Abstract] [Full Text] |
||||
![]() |
Y. L. Ma, R. L. Cain, D. L. Halladay, X. Yang, Q. Zeng, R. R. Miles, S. Chandrasekhar, T. J. Martin, and J. E. Onyia Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation Endocrinology, September 1, 2001; 142(9): 4047 - 4054. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamagishi, E. Otsuka, and H. Hagiwara Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis Endocrinology, August 1, 2001; 142(8): 3632 - 3637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saika, D. Inoue, S. Kido, and T. Matsumoto 17{beta}-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor-{{alpha}} Endocrinology, June 1, 2001; 142(6): 2205 - 2212. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Watkins, Y. Li, H. E. Lippman, and M. F. Seifert Omega-3 Polyunsaturated Fatty Acids and Skeletal Health Experimental Biology and Medicine, June 1, 2001; 226(6): 485 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Han, S. J. Choi, N. Kurihara, M. Koide, Y. Oba, and G. D. Roodman Macrophage inflammatory protein-1{alpha} is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor {kappa}B ligand Blood, June 1, 2001; 97(11): 3349 - 3353. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Horwood, J. Elliott, T. J. Martin, and M. T. Gillespie IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro J. Immunol., April 15, 2001; 166(8): 4915 - 4921. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O. Oyajobi, D. M. Anderson, K. Traianedes, P. J. Williams, T. Yoneda, and G. R. Mundy Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor {{kappa}}B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy Cancer Res., March 1, 2001; 61(6): 2572 - 2578. [Abstract] [Full Text] |
||||
![]() |
M. Takami, N. Takahashi, N. Udagawa, C. Miyaura, K. Suda, J.-T. Woo, T. J. Martin, K. Nagai, and T. Suda Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor-{{kappa}}B Ligand and Osteoprotegerin in Osteoblasts Endocrinology, December 1, 2000; 141(12): 4711 - 4719. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Grcevic, S.-K. Lee, A. Marusic, and J. A. Lorenzo Depletion of CD4 and CD8 T Lymphocytes in Mice In Vivo Enhances 1,25-Dihydroxyvitamin D3-Stimulated Osteoclast-Like Cell Formation In Vitro by a Mechanism That Is Dependent on Prostaglandin Synthesis J. Immunol., October 15, 2000; 165(8): 4231 - 4238. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. GARDINER, P. A. BALDOCK, G. P. THOMAS, N. A. SIMS, N. K. HENDERSON, B. HOLLIS, C. P. WHITE, K. L. SUNN, N. A. MORRISON, W. R. WALSH, et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage FASEB J, October 1, 2000; 14(13): 1908 - 1916. [Abstract] [Full Text] |
||||
![]() |
L. S. HOLLIDAY, S. L. GLUCK, E. SLATOPOLSKY, and A. J. BROWN 1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1857 - 1864. [Abstract] [Full Text] |
||||
![]() |
N. Udagawa, N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, T. Shinki, M. T. Gillespie, T. J. Martin, K. Higashio, et al. Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function Endocrinology, September 1, 2000; 141(9): 3478 - 3484. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Otsuka, Y. Kato, S. Hirose, and H. Hagiwara Role of Ascorbic Acid in the Osteoclast Formation: Induction of Osteoclast Differentiation Factor with Formation of the Extracellular Collagen Matrix Endocrinology, August 1, 2000; 141(8): 3006 - 3011. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Hofbauer and A. E. Heufelder The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2355 - 2363. [Full Text] |
||||
![]() |
L. Huang, J. Xu, D. J. Wood, and M. H. Zheng Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Giant Cell Tumor of Bone : Possible Involvement in Tumor Cell-Induced Osteoclast-Like Cell Formation Am. J. Pathol., March 1, 2000; 156(3): 761 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Itonaga, A Sabokbar, D W Murray, and N A Athanasou Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages Ann Rheum Dis, January 1, 2000; 59(1): 26 - 31. [Abstract] [Full Text] |
||||
![]() |
R. Okazaki, M. Toriumi, S. Fukumoto, M. Miyamoto, T. Fujita, K. Tanaka, and Y. Takeuchi Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption in Vitro Endocrinology, November 1, 1999; 140(11): 5060 - 5065. [Abstract] [Full Text] |
||||
![]() |
R. J. Thomas, T. A. Guise, J. J. Yin, J. Elliott, N. J. Horwood, T. J. Martin, and M. T. Gillespie Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation Endocrinology, October 1, 1999; 140(10): 4451 - 4458. [Abstract] [Full Text] |
||||
![]() |
A. Grey, M.-A. Mitnick, U. Masiukiewicz, B.-H. Sun, S. Rudikoff, R. L. Jilka, S. C. Manolagas, and K. Insogna A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo Endocrinology, October 1, 1999; 140(10): 4683 - 4690. [Abstract] [Full Text] |
||||
![]() |
S.-K. Lee and J. A. Lorenzo Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with Osteoclast-Like Cell Formation Endocrinology, August 1, 1999; 140(8): 3552 - 3561. [Abstract] [Full Text] |
||||
![]() |
L. G. Raisz Physiology and Pathophysiology of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1353 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Collin-Osdoby, L. Rothe, F. Anderson, M. Nelson, W. Maloney, and P. Osdoby Receptor Activator of NF-kappa B and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis J. Biol. Chem., June 1, 2001; 276(23): 20659 - 20672. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhou, V. Kartsogiannis, Y. S. Hu, J. Elliott, J. M. W. Quinn, W. J. McKinstry, M. T. Gillespie, and K. W. Ng A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation J. Biol. Chem., April 27, 2001; 276(18): 14916 - 14923. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Nakchbandi, E. E. Weir, K. L. Insogna, W. M. Philbrick, and A. E. Broadus Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade PNAS, June 20, 2000; 97(13): 7296 - 7300. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Shevde, A. C. Bendixen, K. M. Dienger, and J. W. Pike Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression PNAS, July 5, 2000; 97(14): 7829 - 7834. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |